Entero Therapeutics (ENTO) Company Overview

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Entero Therapeutics, Inc. (NASDAQ: ENTO ), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Halper Sadeh encourages Entero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh.